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GAS MEASUREMENT DEVICE 
2 
the amount of the neutral gas in the sample with a gas 
measurement or gas detection device. 
CROSS-REFERENCE TO RELATED 
APPLICATION(S) 
Other aspects of the invention will become apparent by 
consideration of the detailed description and accompanying 
5 drawings. 
This application claims priority to U.S. Provisional Patent 
Application No. 62/592,323, filed on Nov. 29, 2017, the 
entire contents of which are fully incorporated herein by 
reference. 
BRIEF DESCRIPTION OF THE DRAWINGS 
This patent or application file contains at least one draw-
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention was made with govermnent support under 
grant number DMR 1410192, awarded by the National 
Science Foundation. The government has certain rights in 
the invention. 
IO ing executed in color. Copies of this patent or patent 
application publication with color drawing(s) will be pro-
vided by the Office upon request and payment of the 
necessary fee. 
15 
FIG. 1 shows a schematic of a gas measurement device 
having two chambers separated by glass filter paper coated 
with a layer of PDMS, a layer of polydopamine and a layer 
of gelatin. Cells were cultured on the gelatin top layer; 
cellular NO diffused in all directions; and once NO diffused BACKGROUND 
Devices have been made for the detection and/or mea-
surement of gases in aqueous systems, such as, for example, 
those used for cell culture or for diagnostic or research 
purposes. The detection and measurement of gases in such 
systems may be important to understand how the system 
behaves, and/or for monitoring and control of the system. 
Such devices may be used to measure various gases. 
20 through the PDMS layer into the second (lower) chamber, 
NO was carried into the NOA by a sweep gas for surface flux 
measurement. 
FIG. 2 shows images oflive human dermal fibroblast cells 
(green, stained with calcein) and dead human dermal fibro-
25 blast cells (red, stained with ethidium bromide) on an area 
of a membrane comprising PVDF and PDMS after 48 hours 
of culture. Complete coating of the PVDF with PDMS was 
not achieved on the area where the dead cells were observed. For example, it may be advantageous to detect and or 
measure Nitric Oxide (NO), in aqueous systems that are 
being used for cell culture. NO, which is gaseous under STP 30 
(standard temperature and pressure), is a free radical solute 
that serves as a key signaling molecule in many cellular 
processes. Nitric oxide has been shown to be a potent 
inhibitor of platelet adhesions and activation, plays a role in 
mediating the inflammatory process, and is an antibacterial 35 
agent. NO has anti-apoptotic effects in endothelial cells, 
lymphoma cells, ovarian follicles, cardiac myocytes and 
hepatocytes, and pro-apoptotic properties in macrophages, 
neurons, pancreatic ~-cells, thymocytes chondrocytes, and 
hepatocytes. Some suggest that NO in low levels has a 40 
protective and proliferative effect on cells, while at high 
levels induces cell cycle arrest, senescence, and apoptosis. 
As such, the presence and/or amount of NO in a cell culture 
system may be very important. Moreover, devices that can 
be used for cell culture while also detecting and/or measur- 45 
ing the amount of NO in the aqueous system may be 
particularly advantageous. 
Similarly, systems that allow for the detection and/or 
measurement of gases in aqueous systems can be used to 
observe the effects of gases on compounds and/or compo- 50 
sitions contained within the aqueous system. 
SUMMARY 
FIG. 3 shows a particular embodiment of a device of the 
present disclosure. It comprises two chambers (an upper and 
a lower chamber) separated by a membrane that is perme-
able to neutral gases but impermeable to water that is 
positioned between the first chamber and the second cham-
ber. The membrane includes a first layer comprising PVDF 
and PDMS, wherein the PVDF has a plurality of pores at 
least partially filled with at least some of the PDMS. The first 
(upper) chamber contains an aqueous solution which con-
tains living cells ( e.g., cells that have been cultured). Gas 
associated with the cells, such NO, diffuses in all directions, 
including crossing the membrane into the second (lower) 
chamber of the device, which serves as a gas sampling 
chamber from which cellular NO is collected ( e.g., via a 
sweep gas) and is detected and/or measured with a detector 
( e.g., via chemiluminescence). 
FIG. 4 shows an embodiment of a cell culture experiment 
set-up. Cells were seeded within a first (upper) chamber, the 
illustrated device was placed within a cell incubator for 
normal cell culture, and it was coupled to sampling lines that 
attached to a chemiluminescence NO detector. 
FIG. 5 shows an illustration of how NO sampling can be 
initiated and stopped at any time point during cell culture in 
this particular embodiment. 
FIG. 6 shows how a NO flux measurement was influenced 
In one embodiment, the invention provides a device 
including a first chamber, a second chamber, and a mem-
brane permeable to neutral gases but impermeable to water 
that is positioned between the first chamber and the second 
chamber. The membrane includes a first layer including 
PVDF and PDMS, and the PVDF has a plurality of pores at 
least partially filled with at least some of the PDMS. 
55 by the thickness of an NO permeable membrane. A SNAP-
PDMS disc, which released NO at a specific flux rate (arrow 
A) was were inserted into aqueous solutions contained 
within the upper chambers of gas measurement devices of 
the present disclosure, where each device utilized a PVDF/ 
60 PDMS membrane of differing thickness. The trans-mem-
brane NO flux was measured for devices having membranes 
with a thickness of 17.3±3.2 µm (arrow B), 39.4±4.7 µm 
(arrow C), 53.8±6.2 µm (arrow D), and 162.3±9.5 µm (arrow 
In another embodiment the invention provides a method 
for detecting or measuring the amount of a neutral gas 
associated with an aqueous solution, including: providing 
the aqueous solution in the first chamber of the aforemen- 65 
tioned device, collecting a sample of the neutral gas from the 
second chamber of the device, and detecting or measuring 
E), respectively. 
FIG. 7 shows an SEM image of the surface of the 
foam-like structure of a membrane comprising PVDF and 
PDMS. 
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FIG. 8 shows an SEM image of the cross-section of the 
foam-like structure of a membrane comprising PVDF and 
PDMS. 
4 
real-time fashion. Because of its biological and medical 
significance, NO is used throughout this disclosure as an 
exemplary neutral gas, but other neutral gases, such as N2 (g), 
CO2 (g), O2 (g), H2 O2 (g), CO(g), H2 S(g), NH3 (g), and combi-FIG. 9 shows an embodiment of a two-chamber device 
according to the present disclosure. 5 nations thereof, are explicitly contemplated herein. 
FIG. lOA, FIG. lOB, FIG. lOC, FIG. lOD, and FIG. lOE 
show cross-section SEM images of different thicknesses of 
PDMS membrane generated by multiply casting different 
concentrations of PDMS solutions (for each cast, 72 µl/cm2 
solution was applied), scale bar: 150 µm. FIG. lOA shows 
glass fiber filter paper; FIG. lOB shows 3 repeat of 1 g/10 ml 
RTV-3140 PDMS cast; FIG. lOC shows 1 cast of 1 g/10 ml 
RTV-3140 PDMS and2 repeat of 1 g/8 ml RTV-3140 PDMS 
cast; FIG. lOD shows 1 cast of 1 g/10 ml RTV-3140 PDMS 
and 3 repeat of 1 g/8 ml RTV-3140 PDMS cast; FIG. lOE 15 
shows 1 cast of 1 g/10 ml RTV-3140 PDMS and 4 repeats 
The ability of a previous device ("CellNO trap") to 
measure both the dose and the timing of NO generation has 
been verified by the same inventors in Redox Biology, 8 
(2016) 383-397 and "Systematic study of the biological 
10 effects of nitric oxide (NO) using innovative NO measure-
ment and delivery systems" Michigan Technological Uni-
versity, 2015, each incorporated herein by reference in their 
entirety. 
of 1 g/8 ml RTV-3140 PDMS cast. 
FIG. 11 shows a graph of real-time nitric oxide (NO) 
surface flux (normalized to the cell number) generated from 
HD Fa with ( +) and without (-) stimulation cultured under 20 
normal (5.5 mM) and high glucose (25 mM) conditions 
measured with chemiluminescence detection using an NO 
detection device disclosed herein. 
FIG. 12A, FIG. 12B, FIG. 12C, and FIG. 12D show 
images of cell viability detected by calcein AM and ethidium 25 
bromide for primary human adult dermal fibroblasts cultured 
in normal (5.5 mM) glucose conditions with and without 
stimulation (FIG. 12A, FIG. 12B) and high glucose (25 mM) 
conditions with and without stimulation (FIG. 12C, FIG. 
12D), respectively. Scale bar 500 µm. The results are pre- 30 
sented as the mean+/-standard deviation for n=3, *p<0.05. 
FIG. 13 is a bar graph quantifying the results presented in 
FIG. 12A, FIG. 12B, FIG. 12C, and FIG. 12D. 
FIG. 14 is a bar graph showing total NO compared to 
nitrite accumulation determined for HDFa with and without 35 
In brief, CellNO trap was verified by using a photosen-
sitive NO releasing material, S-nitroso-N-acetylpenicillim-
ine modified poly-dimethylsiloxane (SNAP-PDMS). Mac-
rophages (RA W-264.7) cells were cultured in this device and 
stimulated to demonstrate the ability to measure NO 
released from cells in a real-time, continuous manner. Addi-
tionally, retinal epithelial (ARPE-19) cells, mouse vascular 
smooth muscle (MOVAS) cells, vascular endothelial 
(SVEC) cells, L-929 cell, and mouse primary tenocyte were 
tested in the device to show general applicability of the 
device to multiple cell types. 
Although the CellNO trap device advanced the state of the 
art, it suffers from some significant disadvantages. For 
example, glass fiber filter paper was used in a water tight, 
gas-permeable membrane (FIG. 1), but SNAP-PDMS could 
not be easily applied to the membrane. Additionally, the 
stiffness and smoothness of the membrane needed to be 
markedly improved to, for example, improve adhesion of 
cells to the membrane and the quality of fluorescent cell 
images. 
The unintuitive solution disclosed herein is to replace the 
glass-fiber filter paper in the membrane with PVDF (poly-
vinylidene fluoride). While PVDF has the right mechanical 
properties in terms of rigidity for this application, it was 
unknown whether PVDF could be used for measuring 
stimulation under normal and high glucose conditions. For 
N=3, there is statistically significant difference at p<0.05. * 
normal glucose (LPS/IFN) vs. normal glucose (without 
stimulation); $ normal glucose (LPS/IFN) versus high glu-
cose (LPS/IFN), dots on each average bar indicate indi-
vidual data points. 
FIG. 15A and FIG. 15B are images showing immuno-
fluorescent staining of CD90 (green) in HDFa cultured in 
normal (FIG. 15A) and high glucose (FIG. 15B) conditions. 
Cell nuclei are shown in blue. Scale bar 200 µm. 
40 aqueous systems containing living cells, because PVDF is 
notoriously toxic to cells. It also was unknown whether 
coating PVDF with non-toxic PDMS would lead to cell 
death, and in fact, when PVDF was incompletely covered 
with PDMS, cell death was observed (see FIG. 2). Finally, 
45 it was unclear whether a membrane comprising PVDF and 
PDMS would be sufficiently gas permeable to allow for 
measurement of gases associated with an aqueous system by 
sampling the gas in a chamber on the opposite side of the 
membrane. 
FIG. 16 is a western blot (left) and bar graph (right) 
showing detection of iNOS expression by western blot 
analysis ofHDFa cultured in normal (NG) and high glucose 
(HG) conditions with ( +) and without (-) stimulation. Pre-
dicted band size for iNOS 131 kD and observed band size 50 
125 kD with iNOS and RAW 264.7 (M+ as positive controls. 
MWM-molecular weight marker. Results are quantified in 
the bar graph. 
In the disclosed device, a two-chamber structure (FIG. 3) 
is designed to, for example, allow cells to grow in the first 
(upper) chamber using conventional cell culturing media 
and reagents and, at the same time, sample gas phase NO, for 
example, in the second (lower) chamber. Once cellular NO 
DETAILED DESCRIPTION 
Before any embodiments of the invention are explained in 
detail, it is to be understood that the invention is not limited 
55 diffuses through the interface, NO can be carried by a sweep 
gas into a nitric oxide analyzer (NOA) for continuous, 
real-time measurement. 
in its application to the details of construction and the 
arrangement of components set forth in the following 60 
description or illustrated in the following drawings. The 
invention is capable of other embodiments and of being 
practiced or of being carried out in various ways. 
Disclosed herein, among other things, is an easy and 
reliable device for directly measuring a neutral gas associ- 65 
ated with an aqueous system ( e.g., the flux of a neutral gas, 
such as NO(g), from cultured living cells) continuously in 
In certain embodiments, the device has more than two 
chambers. In certain embodiments, the sweep gas is nitrogen 
or ambient air. Alternately, there may be no sweep gas, such 
as when a measurement or detection device is within the 
second chamber. Typically, the second chamber is in fluid 
communication with a gas detection or gas measurement 
device. 
In certain embodiments, the gas measurement or gas 
detection device comprises a chemiluminescent detection 
device, a electrochemical detection device, an optical detec-
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tion device, an infrared spectroscopy device, a mass spec-
trometry device, a gas chromatography device, or a quartz 
crystal microbalance. 
In certain embodiments, the first chamber contains an 
aqueous solution. The aqueous solution may contain living 5 
cells. The aqueous solution may further contain a polymer. 
The polymer may be a hydrogel. The polymer may be 
adapted to release nitric oxide. 
Akey component of the disclosed device is a water-tight, 
neutral gas permeable membrane used to separate the first 10 
chamber from the second chamber. To create the two inde-
6 
Since PDMS is not a good cell culture substrate, a 
biocompatible polymer can be disposed on the membrane. 
Typically, an intermediate layer of adhesive is necessary 
between the PDMS and the biocompatible polymer. 
ECM component gelatin, for example, can be used for 
surface treatment as a biocompatible polymer. To do this, 
PDMS can be surface treated by coating with dopamine, 
which serves as an intermediate adhesive, and further with 
a gelatin solution applied over the polydopamine layer to 
assist cell adhesion for cell culture. In this case, the layer of 
gelatin also protects the cells from being exposed to PVDF. 
pendent chambers, the membrane at a minimum needs to be 
1) highly permeable to neutral gas (e.g. NO), 2) water 
impermeable, and 3) able to be readily fabricated. In certain 
embodiments, the membrane must also be 4) compatible 
with cell growth. 
Polydimethoxylsiloxane (PDMS) is a preferred compo-
nent of the membrane, because it has a large NO diffusion 
coefficient (up to 3.0xl0-5 cm2/s), is highly hydrophobic 
such that it is impermeable to water, can be modified to be 
biocompatible, and is easy to cast into any shape. PDMS can 
be cast into layers up to 20 mm thick, such that NO diffuses 
through the membrane within one second. This ensures that 
the detection data directly reflects the real-time neutral gas 
released from (or consumed by) the cell layer. 
In certain embodiments, the biocompatible polymer is 
selected from the group consisting of gelatin, fibronectin, 
collagen, specific receptor proteins, antibodies, patterned 
15 DNA, electrospun fibers, cell adhesion matrixes or features, 
naturally or artificially laid down extracellular matrix, other 
cellular polymers, and combinations thereof. 
In certain embodiments, the adhesive is selected from the 
group consisting of polydopamine, organosilanes, PDMS, 
20 modified PDMS, crosslinkers, carbodiimides, gluldahyde, 
and combinations thereof. 
However, since PDMS itself is not stiff enough to provide 
a mechanical support necessary for cell culture, PDMS was 
cast over PVDF. The PVDF provides mechanical strength 
while the PDMS creates a gas permeable, water-tight cham-
ber. 
FIG. 4 illustrates the structure of an embodiment of the 
final device with a cell culture chamber on top and gas 
sampling chamber at the bottom. The assembled device can 
25 be coupled to a chemiluminescence detector and placed 
within an incubator for measuring real-time NO released 
from cells (FIG. 5). 
The disclosed device achieves a real-time cellular gas 
measurement without disturbing the cells under investiga-
The PVDF has a porous structure (FIGS. 7 and 8). The 
PDMS permeates at least a portion of the pores of the PVDF. 
In some embodiments, at least 99% of the pores of the PVDF 
are filled with PDMS. 
To achieve real-time NO measurement, NO gas molecules 
need to pass through the membrane as fast as possible, so 
that it can be detected in real-time. The Einstein-Smolu-
chowski equation describes the net molecule displacement, 
li.x, versus time (t) as (ti.x)2=2Dt, where D represents the 
diffusion coefficient. 
30 tion or deviating from standard cell culturing protocols. This 
device opens up a huge potential for increasing understand-
ing of the role NO and other gases play in both normal and 
pathological conditions in a variety of tissues, and it could 
potentially accelerate the ability to design NO releasing and 
35 generating therapeutic interventions by allowing quantita-
tive understanding of both the dose and temporal aspects of 
NO production in cells. 
40 
To get a small t value, a thin interface and large D are 
required. To achieve this, a diluted RTV-3140/Sylgards 
solution in toluene can be manually cast on PVDF layer by 
layer. A total of3 layers is preferred. Total polymer thickness 
can be well controlled within 20 mm. To control and adjust 45 
the thickness of polymer layer, different concentration of 
RTV-3140 solution (0.1 g/ml and0.125 mg/ml) and different 
number of layers cast can be used. 
In one embodiment, the total coverage of PDMS is about 
4 mg per square centimeter. In another embodiment, the total 50 
coverage of PDMS is less than about 4 mg per square 
centimeter. In yet another embodiment, the total coverage of 
PDMS is greater than about 4 mg per square centimeter. 
In certain embodiments, the membrane has a thickness 
between about 15 µm and about 200 µm. The membrane may 55 
have a total thickness between about 15 and about 200, 
about 25 and about 190, about 35 and about 180, about 45 
and about 170, about 55 and about 160, about 65 and about 
150, about 75 and about 140, about 85 and about 130, about 
95 and about 120, or about 100 and about 115 µm. The 60 
membrane have a total thickness less than or equal to about 
200, about 175, about 150, about 125, about 100, about 75, 
about 50, about 25, about 20, or about 15 µm. The membrane 
may have a total thickness of about 15, 20, 25, 30, 35, 40, 
45,50,55,60, 65, 70, 75, 80,85,90, 95,100,105,110,115, 65 
120,125,130,135, 140,145,150, 155,160,165, 170, 175, 
180, 185, 190, 195, or 200 µm. 
EXAMPLES 
It should be kept in mind that the following described 
embodiments are only presented by way of example and 
should not be construed as limiting the inventive concept to 
any particular physical configuration. 
Example 1 
Cell Culture and Treatment 
Mouse macrophage cell line (RAW264.7) was kept in 
culture in conventional polystyrene petri-dish within com-
plete DMEM (with 10% FBS and 1% penicillin-streptomy-
cin). Cells were scraped off and reseeded into the first 
(upper) chamber of the disclosed device. RAW264.7 cul-
tured within complete media was used as the negative 
control. Cells were stimulated with LPS and/or IFN-y. 
During NO measurement, different reagents which may 
change cellular NO generation profile were administrated to 
cultured cells such that the final concentration of the 
reagents are specified, including arginine (an additional 1 
mM), the arginase inhibitor nor-NOHA (10 µM), and the 
NOS inhibitor L-NAME (50 µM). 
Direct Measurement of NO Release from Cells 
Cells were cultured within the first (upper) chamber using 
standard cell culturing conditions until confluent, unless 
otherwise stated. RA W264. 7 cells were then stimulated with 
LPS and/or IFN-y. The device containing cells was then 
placed into 37° C. 5% CO2 incubator. The second (lower) 
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chamber of the device was connected to NOA. Cellular NO 
generation was measured in PPB/sec (parts per billion/s ), 
converted to moles/sec, and normalized to surface area per 
time to determine the surface flux of NO released by the cell 
layer (nmole cm-2 min- 1). 
Cellular NO Probing by DAF 
DAF-FM stain was dissolved m DMEM to the final 
concentration of 10 µM. The DAF-FM contained media was 
applied to cultured cells and incubated for 20 min at 37° C. 
with 5% CO2 . Media was removed and cells were washed 
twice with PBS; then submerged in PBS and imaged using 
either Zeiss AxioVert 200 M Apo Tome or Olympus BX51 
fluorescent microscope. 
Cell Image by Fluorescent Microscope 
Cells were stained with live-dead assay reagents, 2 µM 
calcein-AM and 2 µg/ml ethidium bromide, in DMEM 
solution for 10 min. Fluorescently labeled cells were imaged 
via Zeiss Axio Vert 200 M Apo Tome fluorescent microscope 
or Olympus BX51 microscope. 
Membrane SEM and AFM Imaging 
8 
remove any extra polydopamine particles that formed. The 
membrane was allowed to air dry. 
Then, the chamber was sterilized by either ethylene oxide 
sterilization (24 h). Alternatively, the plate can be sterilized 
5 by filling with 70% ethanol for 15 min followed by 30 min 
of air drying and 1 hour of exposure to UV light in a bio 
safety cabinet. 
The dopamine-coated membrane in the plate was then 
treated with a solution of gelatin (2 mg/mL Bio-Rad EIA 
10 Grade Reagent Gelatin, cat #170-6537, prepared from DI 
water and can be stored at 4 degree for up to one month) for 
1 h. The volume of gelatin solution (about 5 mL) needed to 
cover the bottom of the plate. Excess solution was poured 
off. The device was air dried for 1 hour and then ready for 
15 cell culture use. 
Two-Chamber NO Delivery Device Design 
A NO delivery set-up was designed to achieve controlled, 
localized NO delivery (FIG. 9). Cells were grown on the 
membrane of the NO measurement system and NO releasing 
20 polymers were applied to the cultured cells from the other 
side of the membrane according to specific needs and then 
removed so that the NO flux was zero after a defined 
delivery time. By connecting this system to a chemilumi-
The prepared semi-permeable membrane was cross-sec-
tioned into 0.5 cm pieces. The membrane was platinum 
coated (50 nm) and imaged with a Hitachi S-4700 FE-SEM. 
Polydopamine and gelatin treated membrane was cut into 
0.5 0.5 cm pieces for topographic image by Veeco Dimen- 25 
sion 3000 at. force microscope. The aluminum reflex coated 
cantilever (Tap300Al-G) was used with a resonance fre-
quency of 300 kHz and a force constant of 40 Nim. 
Statistical Analysis 
nescence detector, actual NO delivered to the cells could be 
monitored. Ethidium bromide was introduced to label dead 
or dying cells for better understanding the cell status. 
However, while RTV-3140 and glass fiber filter paper 
were used to fabricate the NO permeable but water tight 
gas-permeable NO membrane, there were some issues asso-
ciated with the NO permeable membrane, including NO 
releasing polymer SNAP-PD MS could not be easily applied 
The data was analyzed by either student's t-test or one- 30 
way analysis of variance. All statistical assays were achieved 
through R programming, unless specifically noted. 
Fabrication of PVDF Membrane 
to the membrane and the quality of the fluorescent cell image 
and the stiffness of the produced film needed to be markedly 
improved for adhesive cells. Thus, the design of the NO First, a mixture of Dow Coming Sylgard 184 PDMS base 
and curing agent (10:1, w/w) dissolved in hexane was 
vortex-mixed to form 1 :30 (w/v) PDMS solution. 
Then, 1 mL of freshly prepared Sylgard solution was 
manually cast onto a 5 cmx5 cm square of PVDF membrane 
(Bio-Rad Immun-Blot for Protein Blotting) and allowed to 
air dry. This was repeated for a total of 3 times. 
After the organic solvent had air dried, the membrane was 
carefully transferred to a drying oven at 50° C. overnight to 
cure the Sylgard polymer. 
The composite membrane was then cut into a circle to fit 
inside a 60 mm diameter cell culture plate. 
Then, the membrane was attached to the cell culture plate 
that had had its bottom removed ( a 46 mm dia. circle was cut 
from the center of the bottom of the culture dish, leaving a 
3 mm wide rim on the inside of the dish to which the 
membrane is attached to serve as the bottom of the culture 
dish) by wetting the culture dish rim with toluene and 
pressing the membrane to seal in softened polystyrene. 
Then, the lower chamber was fabricated by drilling 2 
holes in the sides of a second culture dish at 90° from each 
other (90-120° was used and confirmed to be sufficient) and 
epoxying 2 frits (Male luer lock barbs, 1/s'' (3.2 mm) ID) into 
the holes. The epoxy was loctite 2-min, 2-part epoxy. 
Then, the chambers were assembled together by aligning 
the upper and lower chambers and applying toluene drop-
wise to melt the plastic together. 
Then, freshly prepared dopamine solution (2 mg/mL, in 
Tris-HCl buffer pH=S.5) was applied into the upper cham-
ber, soaking for 24 h (12 to 20 h was sufficient, and no more 
than 24 h). The polydopamine coating needed exposure to 
ambient oxygen. The volume of dopamine solution (about 5 
mL) needed to cover the membrane; excess solution was 
poured off and the surface was rinsed with DI water to 
35 measurement device was significantly altered. 
Sylgard PDMS replaced RTV-3140 and reproducibly gen-
erated stiffer composite membranes. Glass-fiber filter paper 
was replaced by PVDF (polyvinylidene fluoride) membrane 
(pore size 2 µm). Compared with glass-fiber filter paper, 
40 PVDF has a finer fiber structure. After PDMS polymer was 
cast, the produced membrane displayed a more homoge-
neous and smooth surface, which is very important for 
fluorescent imaging. To manufacture the membrane, the 
mixture ofSylgardPDMS base and curing agent (10:1, w/w) 
45 dissolved in hexane was vortex-mixed to form 1:20 (w/v) 
PDMS solution. The solution was manually cast onto the 
PVDF membrane (72 µl/cm2/cast) and air-dried. Three lay-
ers were cast to form a usable membrane. After the organic 
solvent was air-dried, the membrane was carefully trans-
50 ported into 52° C. heating oven for overnight curing. The 
micro structure of the produced gas-permeable membrane 
was examined by SEM, shown in FIGS. 7 and 8. 
NO Delivery Device Fabrication 
To manufacture the delivery device, a semipermeable 
55 membrane was attached to plastic boxes to form the upper 
chamber of the device for cell culture, as shown in FIG. 9. 
Dopamine solution (1 mg/ml, in Tris-HCl buffer pH=S.5) 
was applied into the upper chamber, soaking for 24 h to 
increase PDMS hydrophilicity; the chamber was ethylene 
60 oxide sterilized and top treated with 2 mg/ml gelatin solution 
for 1 h to facilitate cell adhesion. Then the device was ready 
for cell culture. The lower chamber was produced by adding 
2 ports onto a plastic box, so that the device could be easily 
coupled into an NOA sampling line. Once the two chambers 
65 were placed together, with the SNAP-PDMS polymer disk 
attached directly under the membrane, NO was delivered 
into the upper chamber at a specified flux, which was 
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simultaneously being quantified through sampling NO from 
the lower chamber, as shown the FIGS. 9 and 10, and 
adjusted by the light source underneath the device. 
Because the actual level of NO being delivered to the cells 
was monitored in real-time, the NO generating rate could be 5 
modulated in real-time by adjusting light energy impinged 
on the polymer. 
Since NO flux was mainly controlled by light, to create a 
system that will generate homogeneous NO across the whole 
NO source plane, a homogeneous light source was needed. 10 
A 7x7 LED light array using (VAOL-5GSBY4, Mouser, 
Tex.) LED bulb was fabricated. Blue light LED buds (593-
VAOL-5GSBY4, Mouser) were tin-soldered onto the 
printed circuit board (PCB) to form a 7x7 LED array. An 
LED diffuser (Bright View Tech, Morrisville, N.C.) was 15 
placed over the LED array to homogenize the light. To 
evaluate how homogeneous the light from the source plane 
was, digital pictures of the light source plane were taken 
with a black foam board placed on top of the light source to 
avoid light leaking. ImageJ was used to analyze the digital 20 
photo of the light source and the light intensity distribution. 
The signal strength of each and every pixel of the picture 
indicated a good homogeneity of the light source. 
Controllable NO Delivery Device Build-Up 
To confirm that the NO signal measured in the lower 25 
chamber and the NO entering the upper chamber were 
linearly related and the change was synchronized, two 
identically calibrated NOAs were simultaneously used to 
measure NO flux in real-time from both chambers; different 
LED light intensity was used to manipulate the total NO flux 30 
such that different NO levels in both chambers at different 
time points were recorded in real-time. Linear regression 
analysis was performed to validate the relationship between 
the flux levels measured from both chambers. 
NO released from SNAP-PDMS film either diffused into 35 
the cell culture device or remained in the lower chamber. 
The signal sampled by NOA did not actually represent the 
NO flux experienced by the cells (the idea is the same with 
the two-chamber NO measurement device). 
10 
branes with consistent thickness were manufactured. It was 
determined that a thinner polymer layer is better for NO 
permeability without allowing water leakage. Meanwhile, 
cell growth requires a certain level of overall membrane 
stiffness. If a material is too soft, cell migration and prolif-
eration will be affected, which may introduce significant 
variability in behaviors of standard cell-line models. 
Accordingly, the properties of PDMS/PVDF layer were 
optimized. 
To optimize the thickness of PDMS necessary to provide 
water impermeability and still be thin enough to allow 
necessary gas diffusion, different numbers of membrane 
casting or different concentration of PDMS solutions were 
applied, controlling the amount of PDMS deposited on the 
membrane. RTV-3140 solutions were used to establish the 
thickness requirements (1 g/10 ml toluene and 1.25 g/10 ml 
toluene). By applying varying numbers of layers cast, NO 
permeable composite membranes with different thicknesses 
of PDMS were generated. FIG. 10 shows the control over 
the PDMS layer thickness imaged by SEM; B to E have 
different PDMS layer thicknesses, 17.3±3.2 µm, 39.4±4.7 
µm, 53.8±6.2 µm, 162.3±9.5 µm, respectively.). This 
ensured water impermeability, but allowed gas diffusion. 
To optimize the necessary stiffness of the membrane, 
Sylgard PDMS was used. Different from RTV-3140, the 
PDMS polymer base and the curing agent are supplied 
separately. By using a different base to curing agent ratio and 
different curing temperature, a silicone elastomer with dif-
ferent stiffness can be produced. For the following adhesive 
cell culture, a base: curing agent ratio of 10:1 (w/w) was 
used, and the curing condition was set to 52° C. overnight. 
This stiffness was appropriate for cell culturing and the 
thickness had sufficient water impermeability and gas dif-
fusion to functionally allow the device to work. 
To confirm that the NO signal measured in the lower 
chamber and the NO entering the upper chamber were 
linearly related and the change was synchronized, two 
identically calibrated NOAs were simultaneously used to 
measure NO flux in real-time from both chambers. Different 
40 LED light intensity was used to manipulate the total NO flux 
such that different NO levels in both chambers at different 
The following experiment was completed to determine 
the relationship between the sampled NO flux and NO flux 
that the cultured cells experienced in the upper chamber. The 
SNAP-PD MS disk ( 4 mm diameter, about 340 µm thick) 
was placed under the PDMS membrane as the NO source. 
SNAP-PD MS film was exposed under linearly changed light 45 
intensity by changing LED drive current linearly to generate 
different total NO fluxes while NO in both chambers were 
recorded via two identically calibrated NOAs. 
The NO flux pattern was recorded simultaneously (FIG. 
time points were recorded in real-time. Linear regression 
analysis was performed to validate the relationship between 
the flux levels measured from both chambers. 
Example 3 
Detection of Nitric Oxide in Human Dermal Fibroblast Cells 
Diabetic foot ulcers (DFU) are a major health problem 
associated with diabetes mellitus. Impaired nitric oxide 
(NO) production has been shown to be a major contributor 
to the dysregulation of healing in DFU. However, the level 
of impairment is not known primarily due to challenges with 
measuring NO. The disclosed device was used to measure 
55 NO production in human dermal fibroblasts under normal 
and high glucose conditions. 
6), and the linear regression analysis showed that NO signals 50 
in both chambers did change linearly with each other 
(R=0.9999). The difference of NO signals in the upper and 
lower chamber was observed and the distribution rate was 
determined by the geometry of NO releasing material, 
membrane properties, and the attachment. These results 
suggested that once there is NO generation in the lower 
chamber by using SNAP-PDMS attached to the NO perme-
able membrane, cells cultured on the upper chamber expe-
rienced NO immediately without time delay, and the NO 
signal captured from the lower chamber and the actual NO 
delivered into the upper chamber were linearly related. 
Example 2 
Control Over Membrane Properties 
Since the sensitivity of the NO measurement method 
relies on restricting the thickness of PDMS layer, mem-
Cell Culture and Chemical Supplies: Primary human 
adult dermal fibroblasts (HDFa, ATCC® PCS-201-012™), 
mouse macrophages (RAW 264.7), penicillin streptomycin, 
60 fetal bovine serum (FBS), phosphate buffered saline (PBS), 
3-( 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) proliferation assay kit and Dulbecco's modified 
eagle medium (DMEM high glucose 4500 mg/L) were all 
purchased from ATCC (Manassas, Va., USA). DMEM (no 
65 glucose), sodium pyruvate and Hoescht dye were obtained 
from Fischersci (Hanover Park, Ill., USA). Lipopolysaccha-
ride pseudomonas aeroguinosa (LPS), Calcein-AM, pro-
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tease inhibitor cocktail, mouse nitric oxide synthase and 
dopamine-RC! were purchased from Sigma-Aldrich (St. 
Louis, Mo., USA). Ethidium bromide was acquired from 
Invitrogen (Grand Island, N.Y., USA). Human recombinant 
Interferon (hrIFN-y) was purchased from GenScript (Piscat- 5 
away, N.J., USA). The primary and secondary antibodies 
against CD90/Thyl (ab23894) protein and (iNOS) 
(ab136918) were purchased from Abeam (Cambridge, 
Mass., USA). The 7.5% SDS polyacrylamide gels and 
gelatin were acquired from Bio-Rad (Hercules, Calif., 10 
USA). The Odyssey western blot starter kit 2 was obtained 
from LI-COR (Lincoln, Nebr., USA). Silicone elastomer 
base and curing agent (Dow Corning Sylgard® 184) were 
obtained from ML Solar LLC (Campbell, Calif., USA). 
wave length of 570 nm using a VERSAmax tunable micro-
plate reader model (Molecular devices, Sunnyvale, Calif., 
USA). 
Nitrite Assay: After 24 h of measurement in the CellNO 
trap device, the cell culture media from the cell samples 
under normal and high glucose conditions were collected. 
The triiodide assay was used to measure the nitrite accu-
mulation in the media. Briefly, 50 µL of the media was added 
to a vial containing a stirring solution of 300 µL of glacial 
acetic acid and 120 µL of potassium iodide. The vial was 
connected to a calibrated Sievers Nitric Oxide Analyzer 280i 
(Zysense, LLC, Boulder, Colo., USA) and the NO produced 
from the nitrite present in the media was measured and 
normalized to the number of live cells. 
Real Time NO Measurements from Primary Human Adult 15 
Dermal Fibroblasts: Primary adult dermal fibroblasts at 
passage 1 were cultured and expanded in conventional cell 
culture plates (100 mm) in DMEM (high or normal glucose 
levels), 10% FBS and 1 % penicillin/streptomycin ( complete 
growth media). At confluency, the cells were reseeded in NO 20 
detection devices at a density of0.25-lxl04 cells/cm2 . The 
NO detection devices were generated as described herein. 
Briefly, silicone elastomer base and curing agent were 
dissolved in hexanes, manually cast onto 5x5 cm square 
polyvinylidene fluoride (PVDF) membranes and left to cure 25 
in a 50° C. oven for 24 h. The modified membrane was cut 
Cell Characterization: Fibroblast cells at passage 2 were 
cultured in 12 well plates at a cell density of lxl04 /cm2 in 
normal and high glucose conditions. At confluency, the cells 
were fixed in 4% paraformaldehyde for 10 min, rinsed three 
times in phosphate buffered saline, incubated in blocking 
buffer for 90 min followed by the primary antibody for 18 
h at 4 ° C. The cells were rinsed three times in blocking 
buffer and incubated for 1 h at room temperature with the 
secondary antibody, stained with 4',6-diamidino-2-phenylin-
dole (DAPI) and viewed under a fluorescent microscope. 
Western Blot Analysis: Confluent HDFa cells were cul-
tured in 100 mm diameter tissue culture dishes, stimulated 
with 40 µg/mL of LPS and 200 U/mL IFN-y in normal and 
high glucose conditions and incubated for 72 h. Mouse 
macrophage cells RAW 264.7 were grown to confluency and 
into a circle to fit into a 60 mm diameter cell culture plate 
with the bottom removed forming the upper chamber. The 
upper chamber was sealed by applying toluene to the edges 
of the membrane and the plate. A second 60 mm plate with 
drilled holes and plastic outlets attached was affixed to the 
upper chamber using toluene and reinforced with epoxy 
adhesive. The upper chamber was used for cell culture and 
the lower chamber was used for gaseous transfer. To make 
the device suitable for cell culture, freshly prepared dop-
amine solution in Tris-HCl buffer (2 mg/mL) was added to 
the device and incubated for 12 h. The device was rinsed 
several times and sterilized using 70% ethanol and ultravio-
let light (1 h). Prior to cell culture, the device was coated 
with gelatin solution (2 mg/mL). After 24-72 hours, the cell 
culture media was changed and substituted with media 
containing 40 µg/ml of LPS and 200 U/mL of hr!IFN-y or 
complete growth media (control) under normal glucose (5.5 
mM) and high glucose (25 mM) conditions. The device was 
placed in a standard incubator (37 C, 65% humidity, 5% 
CO2 ) and was connected to a calibrated nitric oxide analyzer 
(NOA) and the real-time NO release profile was measured 
for 24 hours. 
Cell Viability Assay. After 24 h, the live-dead assay was 
carried out using 2 µM calcein AM, 2 µg/mL ethidium 
bromide and 10 µg/mL Hoescht dye in DMEM media for 
10-15 min. The cells were imaged and analyzed using an 
Olympus fluorescent microscope (model BX51) and Image 
J1 respectively. 
Cell Proliferation Assays (MTT Assay): The fibroblast 
cells were cultured in 96 well plates at a density of 10,000 
cells per well in normal and high glucose cell culture 
conditions and stimulated with 40 µg/mL and 200 U/mL of 
LPS and IFN respectively. At the end of 24, 48 and 72 h, 
MTT assay was performed according to the manufacturer's 
instructions (Trevigen, 4890-025-K, Gaithersburg, Md., 
USA) with minor modifications. Briefly, the cell culture 
media was replaced with 25 µL of the MTT reagent and 
incubated for 4 h to allow the intracellular reduction of 
soluble yellow MTT to insoluble formazan dye. The MTT 
reagent was discarded and 100 µL oflsopropyl alcohol was 
added to solubilize the dye. The absorbance was read at a 
30 stimulated with 100 ng/mL of LPS for 18 hand served as the 
positive control. The cells were quickly washed in ice cold 
PBS, trypsinized, centrifuged and re-suspended in 200 µL of 
RIPA buffer in the presence of protease cocktail inhibitors. 
The cell lysates were incubated for 30 min on ice on a plate 
35 shaker and centrifuged at 12,000 rpm for 20 min at 4 ° C. The 
supernatant was collected and the protein concentration 
determined for each sample using Bradford assay. An equal 
amount of.loading buffer containing dithiothreitol was added 
to each sample, boiled at 100° C. for 5 min and immediately 
40 placed on ice for 2 min. About 5.63-9.37 µg of protein was 
loaded in a 7.5% SDS-PAGE gel and separated by electro-
phoresis at 100 V for approximately 70 min. The proteins 
were transferred to Immobilon®-FL PVDF membrane using 
the Trans-Blot® Turbo™ Transfer System (Bio-Rad) for 7 
45 min. The membrane was incubated in Odyssey blocking 
buffer (TBS) for 60 min to block nonspecific binding sites 
followed by incubation in TBS containing 0.2% oftween20 
(TBS-T) and the iNOS antibody (1:1000 dilution) for 18 h 
at 4 ° C. After that, the membrane was washed 4 times with 
50 TBS (0.1% tween20) and incubated in TBS-T with the 
secondary antibody (1 :20,000 dilution) for 1 h then exten-
sively washed in TBS, visualized by LI-COR Odyssey 
infrared imager and analyzed using Image Studio Lite 
software Version 5.2. Statistical analysis was performed in 
55 Microsoft Excel using one-way ANOVA followed by a 
Bonferroni corrected t-test with statistical significance set at 
a 95% confidence level (p<0.05). 
Real-Time NO Detected under Normal and High Glucose 
Conditions: Primary human adult dermal fibroblasts were 
60 cultured in the NO detection device in either normal (5.5 
mM) or high glucose (25 mM) media with and without 
stimulation by the inflarnniatory cytokine interferon garnnia 
(IFN-y) and bacterial endotoxin lipolysaccharide (LPS). The 
NO production was measured for 24 h (FIG. 11). The cells 
65 cultured in normal glucose media in the absence of stimu-
lation showed a slight increase in NO release in the first 1 h 
which peaked at 0.5x10-12 (moles/min·cm2 )/105 cells and 
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remained constant for 24 h. The HDFa cultured in high 
glucose media without stimulation showed an increase in 
NO production which peaked at 0.19xlo- 11 (moles/ 
min·cm2 )/105 cells and remained constant for 24 h. With 
stimulation, there was an increase in the NO production for 5 
cells cultured in normal glucose media, which peaked at 
0.94x10- 11 (moles/min·cm2 )/105 cells and gradually 
dropped to 0.6xl0- 11 (moles/min·cm2 )/105 cells. At 13 h, the 
NOA was disconnected and recalibrated to confirm the 
validity of the signal obtained (Arrow denoting the sudden 10 
drop in curve in FIG. 11). The NO detected remained fairly 
constant around 0.5x10- 11 (moles/min·cm2 )/105 cells up to 
24 h. The NO release for cells cultured in high glucose 
media followed a similar trend but with lower NO detected, 
which peaked at 0.35x10- 11 (moles/min·cm2 )/105 cells at 15 
approximately 4 h and gradually dropped to 0.8lxlo-12 
(moles/min·cm2)/105 cells for 24 h. 
The viability of the cells cultured in the NO detection 
device in normal and high glucose culture conditions with 
and without stimulation by IFN-y and LPS was analyzed by 20 
the live/dead assay at the end of the real-time NO measure-
ments. Cell viability detected by calcein AM and ethidium 
bromide for primary human adult dermal fibroblasts (HD Fa) 
cultured in normal (5.5 mM) glucose condition with and 
without stimulation, (FIG. 12A,B) respectively and high 25 
glucose (25 mM) condition without and with stimulation 
(FIG. 12C,D) respectively. The cells maintained over 95% 
cell viability in all the treatment groups (FIG. 13). 
Nitric Oxide Detected from Nitrite Accumulation in the 
Absence and Presence of Stimulation: After the real-time 30 
NO measurements, the cell culture media was collected and 
analyzed for nitrite using the triiodide assay (FIG. 14). The 
nitrite present in the media is reduced in the presence of an 
acid and nucleophile to produce NO that is measured via 
chemiluminescence detection. Normal glucose conditions 35 
without stimulation had significantly lower NO levels pro-
duced from nitrite compared to normal glucose conditions 
with stimulation (0.73+/-0.05 versus 3.68+/-0.98 nmol/105 
cells, p<0.05 for n=3). In high glucose conditions, there was 
no statistical difference in the levels of NO detected without 40 
stimulation compared to stimulation with LPS/IFN (0.91+/-
0.70 versus 4.26+/-2.11 nmol/105 cells). In the absence of 
stimulation, the NO detected from nitrite in normal glucose 
conditions compared to high glucose were not significantly 
different (0.73+/-0.05 versus 0.91+/-0.70 nmol/105 cells). 45 
Similarly, with stimulation, the NO detected from nitrite was 
not statistically different in normal glucose compared to high 
glucose 3.68+/-0.98 versus 4.26+/-2.11 nmol/105 cells. 
Comparison of Real-Time NO Measurements and Nitrite 
Accumulation: The total NO detected in real-time for the 50 
HDFa was determined by integrating the area under the 
curve (FIG. 11) and was compared to the NO inferred from 
nitrite present in the cell culture media for the 4 treatments 
groups (FIG. 14). The results showed that the levels of 
real-time NO detected in nmol/105 was significantly higher 55 
for cells in normal glucose conditions with stimulation 
(8.42+/-1.16 p<0.05 for n=3) compared to without stimu-
lation (0.48+/-0.31 for n=3 p<0.05). Similarly, under iden-
tical conditions, nitrite accumulation was significantly 
higher in normal glucose with stimulation (3.68+/-0.98) 60 
compared to absence of stimulation (0.73+/-0.05 for n=3 
p<0.05). It is interesting to note that there was a higher direct 
NO measured compared to nitrite. However, high glucose 
conditions did not show the same trend. The levels of 
real-time NO detected with stimulation were not statistically 65 
different from levels of real-time NO without stimulation 
(3.26+/-0.79 and 2.85+/-0.91 nmol/105 cells respectively). 
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The NO levels obtained from nitrite measurement depicted 
a similar trend as the real-time NO measured, with no 
statistical difference in high glucose conditions with stimu-
lation compared to high glucose without stimulation 
(4.26+/-2.11 and 0.91+/-0.70 nmol/105 cells). The real-time 
levels of NO and nitrite detected in normal glucose condi-
tions without stimulation were also not statistically different 
from the real time NO detected from the cells in high 
glucose conditions without stimulation (0.48+/-0.31 and 
3.26+/-0.79 versus 0.73+/-0.05 and 0.91+/-0.70 nmol/105 
cells respectively for n=3 p<0.05). Moreover, in normal 
glucose conditions with stimulation, the levels of real-time 
NO detected was significantly higher compared to high 
glucose conditions with stimulation. The nitrite levels were 
not statistically different. (8.42+/-1.16 and 3.26+/-0.79 ver-
sus 3.68+/-0.98 and 4.26+/-2.11 nmol/105 cells respec-
tively). 
Cell Characterization of HDFa Cultured in Normal and 
High Glucose Conditions: Primary human adult dermal 
fibroblasts cultured in normal and high glucose media were 
assessed for the presence of CD90 (Thy-1), which is a 
reliable molecular marker used to identify fibroblast cells in 
culture. The HDFa maintained uniform staining for CD90 
protein in normal (FIG. 15A) and high glucose conditions 
(FIG. 15B) as well as the elongated and spindle shape that 
is characteristic of confluent fibroblast cells. 
Expression of iNOS Protein in HD Fa Cultured in Normal 
and High Glucose Conditions: Stimulation of fibroblasts by 
inflammatory cytokines and bacterial endotoxins has been 
reported to upregulate the enzyme iNOS, which is directly 
responsible for the production of NO in the cells. The levels 
of iNOS in HD Fa were assessed in cells cultured in normal 
and high glucose conditions with and without stimulation by 
western blot. The results show that overall the iNOS enzyme 
was present in all treatment groups and the protein level was 
very low. Macrophage cell lysates (RAW 264.7) that are 
known to express iNOS when stimulated with LPS and the 
mouse iNOS enzyme protein were used as positive controls. 
Faint iNOS bands can be seen in the human fibroblasts cells, 
which appear at the same molecular weight as the iNOS in 
macrophage cells and the mouse iNOS enzyme (FIG. 16). 
There was no statistical difference in intensity found 
between the groups at p<0.05 for n=3. 
Definitions 
Unless otherwise defined, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art. In case of 
conflict, the present document, including definitions, will 
control. Preferred methods and materials are described 
below, although methods and materials similar or equivalent 
to those described herein can be used in practice or testing 
of the present invention. All publications, patent applica-
tions, patents and other references mentioned herein are 
incorporated by reference in their entirety. The materials, 
methods, and examples disclosed herein are illustrative only 
and not intended to be limiting. 
In its broadest definition, the term "dispersion" is 
intended to include homogeneous solutions, heterogeneous 
solutions, suspensions, colloids, aerosols, sols, emulsions, 
gels, emulsions, foams, and combinations thereof. A disper-
sion may also refer to any one of the aforementioned phases, 
or it may refer to any one of the possible combinations of the 
aforementioned phases. For example, a dispersion could 
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include homogeneous solutions, heterogeneous solutions, 
suspensions, colloids, and emulsions but exclude aerosols 
sols, and gels. ' 
The terms "comprise(s)", "include(s)", "having", "has", 
"can", "contain(s )", and variants thereof, as used herein, are 5 
intended to be open-ended transitional phrases, terms, or 
words that do not preclude the possibility of additional acts 
?r structures. The singular forms "a", "and", and "the" 
mclude plural references unless the context clearly dictates 
otherwise. The present disclosure also contemplates other 10 
embodiments "comprising", "consisting of', and "consisting 
essentially of', the embodiments or elements presented 
herein, whether explicitly set forth or not. 
The conjunctive term "or" includes any and all combina-
tion_s of_ one or more listed elements associated by the 15 
conJunct1ve term. For example, the phrase "an apparatus 
comprising A or B" may refer to an apparatus including A 
where B is not present, an apparatus including B where A is 
not present, or an apparatus where both A and B are present. 
The phrase "at least one of A, B, ... and N" or "at least one 20 
of A, B, ... N, or combinations thereof' are defined in the 
broadest sense to mean one or more elements selected from 
the group comprising A, B, ... and N, that is to say, any 
combination of one or more elements A, B, . . . or N 
including any one element alone or in combination with one 25 
or more of the other elements, which may also include, in 
combination, additional elements not listed. 
. ?1e ~odifier "about" used in connection with a quantity 
1s mclus1ve of the stated value and has the meaning dictated 
by the context (for example, it includes at least the degree of 30 
error associated with the measurement of the particular 
quantity). The modifier "about" should also be considered as 
disclosing the range defined by the absolute values of the 
two endpoints. For example, the expression "from about 2 to 
about 4" also discloses the range "from 2 to 4". The term 35 
"about" may refer to plus or minus 10% of the indicated 
number. For example, "about 10%" may indicate a range of 
9% to 11 %, and "about 1 %" may mean from 0.9-1.1. Other 
meaning~ of"about" may be apparent from the context, such 
as roundmg off, so, for example "about 1" may also mean 40 
from 0.5 to 1 .4. 
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wherein the membrane includes a second layer compris-
ing a biocompatible polymer disposed on the first layer 
between the first layer and the first chamber; 
wherein the biocompatible polymer is selected from the 
group consisting of gelatin, fibronectin, collagen, spe-
cific receptor proteins, antibodies, patterned DNA, 
electrospun fibers, cell adhesion matrixes or features 
extracellular matrix, and combinations thereof. ' 
2. The device of claim 1, wherein the second layer is 
adhered to the first layer with an adhesive. 
3. The device of claim 2, wherein the adhesive is selected 
from the group consisting of poly dopamine, organosilanes, 
PDMS, modified PDMS, crosslinkers, carbodiimides, glul-
dahyde, and combinations thereof. 
4. The device of claim 1, wherein the membrane has a 
thickness between about 15 µm and about 200 µm. 
5. The device of claim 1, wherein the second chamber is 
in fluid communication with a gas detection or gas mea-
surement device. 
6. The device of claim 5, wherein the gas detection or gas 
measurement device is adapted to measure or detect a gas 
selected from the group consisting of NO(g) N CO , 2(g), 2(g), 
O2(g)' H2O2(g)' CO(g)' H2S(g)' NH3 (g)' and combinations 
thereof. 
7. The device of claim 5, wherein the gas measurement or 
gas detection device comprises a chemiluminescent detec-
tion device, an electrochemical detection device, an optical 
detection device, an infrared spectroscopy device, a mass 
spectrometry device, a gas chromatography device, or a 
quartz crystal microbalance. 
8. A method for detecting or measuring the amount of a 
neutral _g~s associated with an aqueous solution, comprising: 
prov1dmg the aqueous solution in the first chamber of the 
device of claim 1; 
collecting a sample of the neutral gas from the second 
chamber of the device; and 
detecting or measuring the amount of the neutral gas in 
the sample with a gas measurement or gas detection 
device. 
9. The method of claim 8, wherein the gas measurement 
or gas detection device is in the second chamber. 
10. The method of claim 8, wherein the gas measurement 
or gas detection device is outside the second chamber. 
11. The method of claim 10, wherein collecting the 
sample comprises moving the sample from the second 
chamber to the gas measurement or gas detection device 
using a sweep gas. 
12. The method of claim 11, wherein the sweep gas 
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comprises nitrogen or ambient air. 
13. The method of claim 8, wherein the aqueous solution 
contains living cells. 
For the recitation of numeric ranges herein, each inter-
vening number there between with the same degree of 
precision is explicitly contemplated. For example, for the 
range of 6-9, the numbers 7 and 8 are contemplated in 45 
addition to 6 and 9, and for the range 6.0-7.0, the number 
6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are 
explicitly contemplated. 
Various features and advantages of the invention are set 
forth in the following claims. 
What is claimed is: 
1. A device comprising: 
a first chamber; 
a second chamber; and 
a membrane permeable to neutral gases but impermeable 55 
to water that is positioned between the first chamber 
and the second chamber; 
14_- !he meth?d of claim 13, further comprising culturing 
the hvmg cells m the aqueous solution. 
15. The method of claim 8, wherein the aqueous solution 
further contains a polymer. 
16. The method of claim 15, wherein the polymer is a 
hydrogel. wherein the membrane includes a first layer comprising 
PVDF and PDMS, wherein the PVDF has a plurality of 
pores at least partially filled with at least some of the 
PDMS; 
17. The method of claim 15, wherein the polymer 1s 
60 
adapted to release nitric oxide. 
* * * * * 
